Oct 17, 2017 ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer's Disease
Sep 28, 2017 ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference
Sep 19, 2017 ProMIS Neurosciences Announces Successful Humanization of Lead Product Candidate PMN310 for Alzheimer's Disease
Sep 13, 2017 ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer's Disease
Jul 5, 2017 ProMIS Neurosciences to Present Preclinical Data from Alzheimer's Disease Program at AAIC 2017